Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. NVDA
6. PRIM
7. META
8. SPY
9. SPCX
10. DPZ

Go back to Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors
Exelixis, Inc. (NASDAQ: EXEL) Delayed: 51.28 -0.07 (0.14%)
Previous Close $51.35    52 Week High $17.00 
Open $51.47    52 Week Low $3.55 
Day High $51.68    P/E N/A 
Day Low $51.04    EPS $-1.33 
Volume 143,476